All individual trials at Aerpio Therapeutics

0 out of 1

0.0%

$20,453,992

Status	Sponsor	Trial ID	Title	Completion date	Days overdue
overdue	Aerpio Therapeutics	NCT02387788	Phase 2a Open Label Study to Assess the Efficacy and Safety of Subcutaneous 15mg AKB-9778 Administered Twice Daily for 84 Days in Subjects With Retinal Vein Occlusion [pACT]	2017-04-30	1798

Download this data